Profusa (NASDAQ:PFSA – Get Free Report) and ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk.
Insider & Institutional Ownership
9.8% of Profusa shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 15.0% of Profusa shares are owned by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Profusa has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.
Profitability
This table compares Profusa and ClearPoint Neuro’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Profusa | N/A | N/A | -1,731.09% |
| ClearPoint Neuro | -79.43% | -188.08% | -39.01% |
Analyst Recommendations
This is a summary of current ratings for Profusa and ClearPoint Neuro, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Profusa | 1 | 0 | 0 | 0 | 1.00 |
| ClearPoint Neuro | 1 | 0 | 2 | 0 | 2.33 |
ClearPoint Neuro has a consensus target price of $24.33, indicating a potential upside of 144.56%. Given ClearPoint Neuro’s stronger consensus rating and higher possible upside, analysts plainly believe ClearPoint Neuro is more favorable than Profusa.
Earnings and Valuation
This table compares Profusa and ClearPoint Neuro”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Profusa | $100,000.00 | 3.97 | -$35.82 million | ($5,619.96) | -0.00 |
| ClearPoint Neuro | $45.49 million | 7.01 | -$25.54 million | ($1.21) | -8.22 |
ClearPoint Neuro has higher revenue and earnings than Profusa. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.
Summary
ClearPoint Neuro beats Profusa on 10 of the 13 factors compared between the two stocks.
About Profusa
NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.
About ClearPoint Neuro
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.
